Silverberg Bernstein Capital Management LLC Acquires 250,167 Shares of Apyx Medical Corporation $APYX

Key Points

• Silverberg Bernstein Capital Management LLC increased its stake in Apyx Medical Corporation by 38.7%, owning 896,736 shares after acquiring an additional 250,167 shares during the second quarter.
• Apyx Medical reported a quarterly EPS of ($0.09), in line with analyst estimates, and a revenue of $11.37 million, slightly below projections of $11.69 million.
• The company's stock has a market capitalization of $80.56 million and trades at $2.13, with a one-year high of $2.73 and a low of $0.76.

Silverberg Bernstein Capital Management LLC grew its holdings in Apyx Medical Corporation (NASDAQ:APYX - Free Report) by 38.7% during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 896,736 shares of the company's stock after purchasing an additional 250,167 shares during the period. Apyx Medical comprises 1.4% of Silverberg Bernstein Capital Management LLC's portfolio, making the stock its 19th largest holding. Silverberg Bernstein Capital Management LLC owned about 2.37% of Apyx Medical worth $2,018,000 as of its most recent SEC filing.

Other hedge funds have also recently added to or reduced their stakes in the company. Citadel Advisors LLC boosted its position in shares of Apyx Medical by 130.6% in the fourth quarter. Citadel Advisors LLC now owns 66,355 shares of the company's stock valued at $105,000 after acquiring an additional 37,582 shares during the period. Northern Trust Corp raised its holdings in Apyx Medical by 27.9% during the 4th quarter. Northern Trust Corp now owns 132,251 shares of the company's stock worth $209,000 after purchasing an additional 28,865 shares during the last quarter. Kingsview Wealth Management LLC increased its stake in shares of Apyx Medical by 29.5% in the 1st quarter. Kingsview Wealth Management LLC now owns 175,095 shares of the company's stock valued at $240,000 after acquiring an additional 39,850 shares during the last quarter. Strategic Advisors LLC bought a new stake in shares of Apyx Medical in the 1st quarter valued at about $27,000. Finally, Nantahala Capital Management LLC boosted its position in Apyx Medical by 2.8% during the 1st quarter. Nantahala Capital Management LLC now owns 3,258,048 shares of the company's stock worth $4,464,000 after acquiring an additional 88,248 shares during the last quarter. Institutional investors and hedge funds own 55.33% of the company's stock.

Apyx Medical Stock Performance

APYX traded up $0.05 during trading hours on Friday, reaching $2.29. The company's stock had a trading volume of 66,704 shares, compared to its average volume of 44,919. The company has a debt-to-equity ratio of 4.61, a quick ratio of 3.95 and a current ratio of 4.72. The firm has a market cap of $86.61 million, a PE ratio of -5.09 and a beta of 1.43. The company's 50-day moving average is $2.09 and its 200-day moving average is $1.66. Apyx Medical Corporation has a 52 week low of $0.76 and a 52 week high of $2.73.

Apyx Medical (NASDAQ:APYX - Get Free Report) last released its quarterly earnings data on Thursday, August 7th. The company reported ($0.09) earnings per share for the quarter, meeting the consensus estimate of ($0.09). Apyx Medical had a negative return on equity of 158.22% and a negative net margin of 37.11%.The business had revenue of $11.37 million for the quarter, compared to analyst estimates of $11.69 million. Apyx Medical has set its FY 2025 guidance at EPS. On average, equities analysts forecast that Apyx Medical Corporation will post -0.68 EPS for the current year.

Apyx Medical Company Profile

Apyx Medical Corporation, an energy technology company, engages in the design, development, and manufacture of medical devices in the United States and internationally. The company operates through two segments: Advanced Energy and Original Equipment Manufacturing (OEM). It offers Helium Plasma Generator for delivery of RF energy and helium plasma to cut, coagulate, and ablate soft tissue during open and minimally invasive surgical procedures.